Alison – Interview 14
Alison talks about her experiences of three different clinical trials since the birth of her son. Two whilst in the neonatal unit of which one she was not eligible. The third trial involved her son receiving Growth Hormone Treatment.
Alison, aged 39 years lives with her husband and three children. Her son was diagnosed with Intrauterine Growth Restriction at 22 weeks. Alison gave birth to her son at 30 weeks; he weighed 2lbs. Because of this they spent quite a long time in a neonatal unit and also in a paediatric ward. As such she was suitable and eligible for a number of clinical trials.
The first trial Alison was offered while she was pregnant. It was assumed that as her baby had stopped growing he would require a ventilator at birth. Both Alison and her husband were given quite a lot of information in a very short space of time. She says this was okay and the consultant was absolutely lovel and was available to answer any questions they may have had. Alison found this to be very reassuring;. Although on reflection, she says it was an incredibly difficult time. I had a, a very high-risk pregnancy and I was losing a lot of blood as well as the, the problem of the baby not growing. So I actually did leave a lot of decisions to my husband. I wasn’t really in a fit state to be able to do very muc. Despite all this Alison says she feels happy that she agreed to take part. However, as it turned out when her son was born he was breathing unaided so he was not eligible and they didn’t take part in the trial.
The second trial, a randomised control trial, involved preterm babies that weighted under a kilo and looked at whether the use of antibiotics were effective in reducing sepsis; sepsis being a primary cause for neonatal mortality. Alison was randomised into the treatment group, so her son received the antibiotic. Alison and her husband received plenty of information about the trial, its purpose and what was involved. Her son was followed up at two years and five years. Throughout this time there was very good communications between them and the hospital. Alison recalls that they received a newsletter every six months to give an update about the study; numbers recruited and progress. However, the results of the trial showed that the use of antibiotics does not make any difference and as such will not be used in neonatal medicine. Alison admits that she was surprised at the results because they were led to believe it was a very positive thing and had proven success in paediatric medicine. She reflects that her son would have been given antibiotics anyway and that the only impact it had on family life was an extra two-year appointment that was conveniently backed onto a hospital appointment.
As growth, weight and height had remained a problem for her son, when he was four years of age she agreed for him to receive growth hormone treatment. It was at this stage that they were asked to take part in a third clinical trial. However, Alison says this was a hard decision, mainly due to time. The trial involves her son having daily growth hormone injections to make him grow at a normal rate. The purpose of the trial was to determine the best dose as there were conflicting models across Europe and America. Within a year her son had caught up and was now growing at a normal rate, but he continues to receive a dose of growth hormone to maintain this growth, but they have now decided to withdraw from the trial after four years.
Overall Alison has no regrets in taking part in any of the trials and is supportive of medical research in general.